Rocket


Overview
Financials
News + Filings
Key Docs
Ownership


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Gracell Biotechnologies Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 144 Form 144 - Report of proposed sale of securities:
09/29/2023 6-K Quarterly results
09/27/2023 6-K Quarterly results
08/24/2023 F-3 Form F-3 - Registration statement by foreign private issuers:
08/23/2023 144 Form 144 - Report of proposed sale of securities:
08/21/2023 SC 13G RA CAPITAL MANAGEMENT, L.P. reports a 10% stake in GRACELL BIOTECHNOLOGIES INC.
08/18/2023 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals:
08/14/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"​",
"​"
08/11/2023 SC 13D/A ORBIMED ADVISORS LLC reports a 8% stake in Gracell Biotechnologies Inc.
08/07/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Form of Subscription Agreement between Gracell Biotechnologies Inc. and investors",
"Form of Subscription Agreement between Gracell Biotechnologies Inc. and investors",
"Gracell Biotechnologies Announces Up to $150 Million Private Placement Financing Joined by a Syndicate of Premier Healthcare Investors",
"Corporate Presentation, August 2023"
07/14/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Amendment to the Fourth Amended and Restated Memorandum of Association",
"Amendment to the Fourth Amended and Restated Memorandum of Association"
06/16/2023 144 Form 144 - Report of proposed sale of securities:
05/16/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Gracell Biotechnologies Reports First Quarter 2023 Unaudited Financial Results, and Provides Corporate Update"
04/25/2023 20-F Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
03/31/2023 SC 13D ORBIMED ADVISORS LLC reports a 11.2% stake in Gracell Biotechnologies Inc.
03/16/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
03/15/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
03/14/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Gracell Biotechnologies Reports Fourth Quarter and Full Year 2022 Unaudited Financial Results, and Provides Corporate Update"
03/08/2023 SC 13G/A BlackRock Inc. reports a 4.5% stake in DOXIMITY INC CLASS A
02/14/2023 SC 13G/A Frazier Life Sciences Public Fund, L.P. reports a 0% stake in Gracell Biotechnologies Inc.
02/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/07/2023 SC 13G/A William Cao Wei reports a 26.9% stake in Gracell Biotechnologies Inc.
02/07/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Gracell Biotechnologies Announces FDA Clearance of the IND Application for Phase 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Relapsed/Refractory Multiple Myeloma"
02/06/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/03/2023 SC 13G BlackRock Inc. reports a 7.2% stake in GRACELL BIOTECHNOLOGIES INC.
02/01/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
01/06/2023 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "Company Presentation",
"Company Presentation"
12/16/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed Multiple Myeloma at 64 th American Society of Hematology Annual Meeting & Exposition"
11/16/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Gracell Biotechnologies Wins 2022 Fierce Life Sciences Innovation Award"
11/16/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Gracell Biotechnologies Reports Third Quarter 2022 Unaudited Financial Results and Provides Corporate Update"
10/18/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K",
"Gracell Biotechnologies Doses First Patient in Phase 2 Portion of Registrational Phase 1/2 Clinical Trial Evaluating GC007g for Treatment of B-cell Acute Lymphoblastic Leukemia"
09/15/2022 6-K Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
Docs: "FORM 6-K"
08/15/2022 6-K Quarterly results
08/15/2022 6-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy